Review ArticleReview Article
Open Access

An insight into the molecular characteristics of hepatitis C virus for clinicians

Lingyao Du and Hong Tang
Saudi Medical Journal May 2016, 37 (5) 483-491; DOI: https://doi.org/10.15537/smj.2016.5.14178

References

  1. ↵
    1. Feinstone SM,
    2. Kapikian AZ,
    3. Purcell RH,
    4. Alter HJ,
    5. Holland PV
    (1975) Transfusion-associated hepatitis not due to viral-hepatitis type-a or type-B. N Engl J Med 292:767–770.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Choo QL,
    2. Kuo G,
    3. Weiner AJ,
    4. Overby LR,
    5. Bradley DW,
    6. Houghton M
    (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359–362.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Mohd Hanafiah K,
    2. Groeger J,
    3. Flaxman AD,
    4. Wiersma ST
    (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333–1342.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    (2014) First WHO hepatitis C treatment guidelines. B World Health Organ 92:312–313.
    OpenUrl
  5. ↵
    1. Brass V,
    2. Moradpour D,
    3. Blum HE
    (2006) Molecular virology of hepatitis C virus (HCV): 2006 update. Int J Med Sci 3:29–34.
    OpenUrlPubMed
  6. ↵
    1. Wang CY,
    2. Sarnow P,
    3. Siddiqui A
    (1993) Translation of human hepatitis-C virus-Rna in cultured-cells is mediated by an internal ribosome-binding mechanism. J Virol 67:3338–3344.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Friebe P,
    2. Lohmann V,
    3. Krieger N,
    4. Bartenschlager R
    (2001) Sequences in the 5’ nontranslated region of hepatitis C virus required for RNA replication. J Virol 75:12047–12057.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Friebe P,
    2. Bartenschlager R
    (2002) Genetic analysis of sequences in the 3 ’ nontranslated region of hepatitis C virus that are important for RNA replication. J Virol 76:5326–5338.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Hijikata M,
    2. Kato N,
    3. Ootsuyama Y,
    4. Nakagawa M,
    5. Shimotohno K
    (1991) Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci U S A 88:5547–5551.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Lindenbach BD,
    2. Evans MJ,
    3. Syder AJ,
    4. Wolk B,
    5. Tellinghuisen TL,
    6. Liu CC,
    7. et al.
    (2005) Complete replication of hepatitis C virus in cell culture. Science 309:623–626.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Tang H,
    2. Grise H
    (2009) Cellular and molecular biology of HCV infection and hepatitis. Clin Sci (Lond) 117:49–65.
    OpenUrl
  12. ↵
    1. Koutsoudakis G,
    2. Kaul A,
    3. Steinmann E,
    4. Kallis S,
    5. Lohmann V,
    6. Pietschmann T,
    7. et al.
    (2006) Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 80:5308–5320.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Agnello V,
    2. Abel G,
    3. Elfahal M,
    4. Knight GB,
    5. Zhang QX
    (1999) Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 96:12766–12771.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Wunschmann S,
    2. Medh JD,
    3. Klinzmann D,
    4. Schmidt WN,
    5. Stapleton JT
    (2000) Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 74:10055–10062.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Meuleman P,
    2. Hesselgesser J,
    3. Paulson M,
    4. Vanwolleghem T,
    5. Desollibere I,
    6. Reiser I,
    7. et al.
    (2008) Anti-CD81 antibodies can prevent a hepatitis c virus infection in vivo. Hepatology 48:1761–1768.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Catanese MT,
    2. Graziani R,
    3. von Hahn T,
    4. Moreau M,
    5. Huby T,
    6. Paonessa G,
    7. et al.
    (2007) High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 81:8063–8071.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Evans MJ,
    2. von Hahn T,
    3. Tscherne DM,
    4. Syder AJ,
    5. Panis M,
    6. Wolk B,
    7. et al.
    (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801–805.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Meertens L,
    2. Bertaux C,
    3. Cukierman L,
    4. Cormier E,
    5. Lavillette D,
    6. Cosset FL,
    7. et al.
    (2008) The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol 82:3555–3560.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Ploss A,
    2. Evans MJ,
    3. Gaysinskaya VA,
    4. Panis M,
    5. You HN,
    6. de Jong YP,
    7. et al.
    (2009) Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882–886.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Gosert R,
    2. Egger D,
    3. Lohmann V,
    4. Bartenschlager R,
    5. Blum HE,
    6. Bienz K,
    7. et al.
    (2003) Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 77:5487–5492.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. El-Hage N,
    2. Luo G
    (2003) Replication of hepatitis C virus RNA occurs in a membrane-bound replication complex containing nonstructural viral proteins and RNA. J Gen Virol 84(Pt 10):2761–2769.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Huang H,
    2. Sun F,
    3. Owen DM,
    4. Li WP,
    5. Chen Y,
    6. Gale M,
    7. et al.
    (2007) Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. P Natl Acad Sci USA 104:5848–5853.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Chang KS,
    2. Jiang JY,
    3. Cai ZH,
    4. Luo GX
    (2007) Human apolipoprotein E is required for infectivity and production of hepatitis C virus in cell culture. J Virol 81:13783–13793.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Gastaminza P,
    2. Kapadia SB,
    3. Chisari FV
    (2006) Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol 80:11074–11081.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Ma YH,
    2. Anantpadma M,
    3. Timpe JM,
    4. Shanmugam S,
    5. Singh SM,
    6. Lemon SM,
    7. et al.
    (2011) Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins. J Virol 85:86–97.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Guidotti LG,
    2. Chisari FV
    (2006) Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1:23–61.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Choi J,
    2. Ou JH
    (2006) Mechanisms of liver injury III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 290:G847–G851.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Miura K,
    2. Taura K,
    3. Kodama Y,
    4. Schnabl B,
    5. Brenner DA
    (2008) Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 48:1420–1429.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Machida K,
    2. Cheng KT,
    3. Sung VM,
    4. Shimodaira S,
    5. Lindsay KL,
    6. Levine AM,
    7. et al.
    (2004) Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A 101:4262–4267.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Pekow JR,
    2. Han AK,
    3. Zheng H,
    4. Chung RT
    (2007) Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis c-related cirrhosis. Cancer 109:2490–2496.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Lonardo A,
    2. Loria P,
    3. Adinolfi LE,
    4. Carulli N,
    5. Ruggiero G
    (2006) Hepatitis C and steatosis: a reappraisal. J Viral Hepatitis 13:73–80.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Kasprzak A,
    2. Adamek A
    (2008) Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res 38:1–26.
    OpenUrlCrossRefPubMed
    1. Deng L,
    2. Nagano-Fujii M,
    3. Tanaka M,
    4. Nomura-Takigawa Y,
    5. Ikeda M,
    6. Kato N,
    7. et al.
    (2006) NS3 protein of Hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. J Gen Virol 87(Pt 6):1703–1713.
    OpenUrl
  34. ↵
    1. Majumder M,
    2. Ghosh AK,
    3. Steele R,
    4. Ray R,
    5. Ray RB
    (2001) Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. Journal of Virology 75:1401–1407.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Cho JW,
    2. Baek WK,
    3. Yang SH,
    4. Chang J,
    5. Sung YC,
    6. Suh MH
    (2001) HCV core protein modulates Rb pathway through pRb down-regulation and E2F-1 up-regulation. Bba-Mol Cell Res 1538:59–66.
    OpenUrl
  36. ↵
    1. Munakata T,
    2. Liang Y,
    3. Kim S,
    4. McGivern DR,
    5. Huibregtse J,
    6. Nomoto A,
    7. et al.
    (2007) Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog 3:1335–1347.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Lundin M,
    2. Monne M,
    3. Widell A,
    4. von Heijne G,
    5. Persson MAA
    (2003) Topology of the membrane-associated hepatitis C virus protein NS4B. Journal of Virology 77:5428–5438.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Park JS,
    2. Yang JM,
    3. Min MK
    (2000) Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. Biochem Biophys Res Commun 267:581–587.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Einav S,
    2. Sklan EH,
    3. Moon HM,
    4. Gehrig E,
    5. Liu P,
    6. Hao Y,
    7. et al.
    (2008) The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without ha-ras co-transfection. Hepatology 47:827–835.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Morisco F,
    2. Granata R,
    3. Stroffolini T,
    4. Guarino M,
    5. Donnarumma L,
    6. Gaeta L,
    7. et al.
    (2013) Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 19:2793–2798.
    OpenUrlPubMed
  41. ↵
    1. De Clercq E
    (2014) Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem Pharmacol 89:441–452.
    OpenUrlCrossRef
  42. ↵
    1. Kanda T,
    2. Yokosuka O,
    3. Omata M
    (2015) Faldaprevir for the treatment of hepatitis C. Int J Mol Sci 16:4985–4996.
    OpenUrl
  43. ↵
    1. Rangnekar AS,
    2. Fontana RJ
    (2012) Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther 36:104–114.
    OpenUrlPubMed
  44. ↵
    (2015) EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 63:199–236.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Chae HB
    (2015) [New Therapeutic Agent for Chronic Hepatitis C: Direct Acting Agent]. Korean J Gastroenterol 66:5–9.
    OpenUrl
  46. ↵
    1. Kiser JJ,
    2. Burton JR Jr.
    (2013) Everson GT Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 10:596–606.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Gritsenko D,
    2. Hughes G
    (2015) Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. P T 40:256–276.
    OpenUrl
  48. ↵
    1. Krishnan P,
    2. Beyer J,
    3. Mistry N,
    4. Koev G,
    5. Reisch T,
    6. DeGoey D,
    7. et al.
    (2015) In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 59:979–987.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Pilot-Matias T,
    2. Tripathi R,
    3. Cohen D,
    4. Gaultier I,
    5. Dekhtyar T,
    6. Lu L,
    7. et al.
    (2015) In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 59:988–997.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Hughes M,
    2. Griffin S,
    3. Harris M
    (2009) Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. J Gen Virol 90:1329–1334.
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    1. Gao M,
    2. Nettles RE,
    3. Belema M,
    4. Snyder LB,
    5. Nguyen VN,
    6. Fridell RA,
    7. et al.
    (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96–100.
    OpenUrlCrossRefPubMedWeb of Science
  52. ↵
    1. Garimella T,
    2. Wang R,
    3. Luo WL,
    4. Wastall P,
    5. Kandoussi H,
    6. DeMicco M,
    7. et al.
    (2015) Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine/naloxone. Antimicrob Agents Chemother 59:5503–5510.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Hill L
    (2015) Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment. Top Antivir Med 23:92–96.
    OpenUrlPubMed
  54. ↵
    1. Garimella T,
    2. Wang R,
    3. Luo W,
    4. Hwang C,
    5. Sherman D,
    6. Kandoussi H,
    7. et al.
    (2014) The effect of renal impairment on single-dose pharmacokinetics of daclatasvir, an HCV NS5A inhibitor. J Viral Hepatitis 21:32.
    OpenUrl
  55. ↵
    1. Garimella T,
    2. Wang R,
    3. Luo WL,
    4. Hwang C,
    5. Sherman D,
    6. Kandoussi H,
    7. et al.
    (2015) Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther 20:535–543.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Kwon HJ,
    2. Xing W,
    3. Chan K,
    4. Niedziela-Majka A,
    5. Brendza KM,
    6. Kirschberg T,
    7. et al.
    (2015) Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent. PLoS One 10:e0122844.
    OpenUrlCrossRefPubMed
  57. ↵
    1. Gane EJ,
    2. Stedman CA,
    3. Hyland RH,
    4. Ding X,
    5. Svarovskaia E,
    6. Symonds WT,
    7. et al.
    (2013) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368:34–44.
    OpenUrlCrossRefPubMedWeb of Science
  58. ↵
    1. Kayali Z,
    2. Schmidt WN
    (2014) Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. Pharmgenomics Pers Med 7:387–998.
    OpenUrlCrossRef
  59. ↵
    1. Sulkowski MS,
    2. Gardiner DF,
    3. Rodriguez-Torres M,
    4. Reddy KR,
    5. Hassanein T,
    6. Jacobson I,
    7. et al.
    (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. italic>N Engl J Med 370:211–221.
    OpenUrl
  60. ↵
    1. Afdhal N,
    2. Reddy KR,
    3. Nelson DR,
    4. Lawitz E,
    5. Gordon SC,
    6. Schiff E,
    7. et al.
    (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:1483–1493.
    OpenUrlCrossRefPubMedWeb of Science
  61. ↵
    1. Dvory-Sobol H,
    2. Voitenleitner C,
    3. Mabery E,
    4. Skurnac T,
    5. Lawitz EJ,
    6. McHutchison J,
    7. et al.
    (2014) Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 58:6599–6606.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Kato N,
    2. Sekiya H,
    3. Ootsuyama Y,
    4. Nakazawa T,
    5. Hijikata M,
    6. Ohkoshi S,
    7. et al.
    (1993) Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 67:3923–3930.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Zibert A,
    2. Dudziak P,
    3. Schreier E,
    4. Roggendorf M
    (1997) Characterization of antibody response to hepatitis C virus protein E2 and significance of hypervariable region 1-specific antibodies in viral neutralization. Arch Virol 142:523–534.
    OpenUrlCrossRefPubMed
  64. ↵
    1. El-Attar LMR,
    2. Partidos CD,
    3. Howard CR
    (2010) A Peptide mimotope of hepatitis c virus e2 protein is immunogenic in mice and block human anti-HCV sera. J Med Virol 82:1655–1665.
    OpenUrlPubMed
  65. ↵
    1. Triyatni M,
    2. Berger EA,
    3. Saunier B
    (2011) A new model to produce infectious hepatitis C virus without the replication requirement. PLoS Pathog 7:e1001333.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section